Abstract：Objective: To investigate the expression of Artemin, CXCL13 and MMP-9 in endometrial carcinoma, atypical hyperplasia, simple hyperplasia and normal endometrial tissue, and in different clinicopathological features of endometrial carcinoma. The relationship between differential expression and clinical pathological staging of endometrial carcinoma. Methods: A total of 154 cases of endometrial specimens were removed from the Department of Gynecology, Affiliated Hospital of Chengde Medical College from June 2016 to April 2018, including 78 cases of endometrial carcinoma, 56 cases of stage I (EC-I group), 15 cases of stage II (EC-II group), 7 cases of stage III (EC-III group), 32 cases of atypical proliferative endometrial tissue (EAH group), 46 cases of simple proliferative endometrial tissue (ESH group), normal endometrial tissue in 44 cases (NE group). The expression of Artemin, CXCL13 and MMP-9 in endometrial carcinoma, atypical hyperplasia, simple hyperplasia and normal endometrium was detected by Western Blot. Real-time quantitative PCR was used to detect Artemin, CXCL13 and MMP-9 mRNA. The expression of different clinicopathological features in endometrial carcinoma tissues was analyzed, and the relationship between differential expression and clinical pathological staging of endometrial carcinoma was analyzed. Results:: The expression of Artemin, CXCL13 and MMP-9 in the EC group were higher than those in the EAH group, ESH group and NE group (F=38.54, F=98.74, F=72.46, all P<0.05). The expression of Artemin, CXCL13 and MMP-9 mRNA in endometrial carcinoma was correlated with depth of myometrial invasion, pathological differentiation, FIGO stage and lymph node metastasis (all P <0.05), which was not correlated with age (P >0.05). Conclusion: Artemin, CXCL13 and MMP-9 play a role in the development of endometrial carcinoma, which may provide new research direction for early diagnosis and prognosis of endometrial carcinoma.
[1] Makker A, Gole M. Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update[J]. Endocr Relat Cancer, 2016, 23(2): 85~111. [2] Kamal H, Jiahao J, Fumou S, et al. Artemin promotes oncogenicity, metastasis and drug resistance in cancer cells[J]. Reviews in the neurosciences, 2018, 29(1): 93~98. [3] Irshad S,Flores-Borja F,Lawler K,et al. RORgammat +innate lymphoid cells promote lymph node metastasis of breast cancer[J]. Cancer Res,2017,77 (5):1083~1096. [4] Mirolyuba I,Janne N, Irina K, et al . Artemin and an artemin-derived peptide, artefin, induce neuronal survival and differentiation through ret and NCAM[J]. Frontiers molecular neuroscience, 2019, 12(1): 47~56. [5] 柴松,牛韧,江中太,等.LncRNAAFAP1-AS1对食管鳞癌细胞株EC9706转移潜能影响机制探讨[J].中华肿瘤防治杂志,2016,23(18):1218~1223. [6] 张路漫,田刚魏,殿军.乳腺癌侵袭转移中Artemin作用的探讨[J].天津医科大学学报,2018,24(4):284~286. [7] 曹学全,卢洪胜,章辉,等.胃癌组织Artemin和MMP-9表达与浸润转移相关性分析[J].中华肿瘤防治杂志,2013,20(4):266~268. [8] Ammirante M, Shalapour S, Kang Y, et al. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts[J]. Proc Nat Acad Sci USA, 2014, 111(41): 14776~14781. [9] Gu-Tranlien C, Migliori E, Buisseret L, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer[J]. JCI Insight, 2017, 2(11): pii: 91487. [10] Qi XW, Xia SH, Yin Y, et al. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer [J]. Eur Rev Med pharmacol sci, 2014, 18(13): 1916~1924. [11] Fan L, Zhu Q, Liu L, et al. CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion[J]. Oncotarget, 2017, 8(32): 53244~53261.
2019, Vol. 25 
冀公网安备13080202000677号